Metformin: Experimental and Clinical Evidence for a Potential Role in Emphysema Treatment.

TitleMetformin: Experimental and Clinical Evidence for a Potential Role in Emphysema Treatment.
Publication TypeJournal Article
Year of Publication2021
AuthorsPolverino F, Wu TDavid, Rojas-Quintero J, Wang X, Mayo J, Tomchaney M, Tram J, Packard S, Zhang D, Cleveland KH, Cordoba-Lanus E, Owen CA, Fawzy A, Kinney GL, Hersh CP, Hansel NN, Doubleday K, Sauler M, Tesfaigzi Y, Ledford JG, Casanova C, Zmijewski J, Konhilas J, Langlais PR, Schnellmann R, Rahman I, McCormack M, Celli B
JournalAm J Respir Crit Care Med
Volume204
Issue6
Pagination651-666
Date Published2021 09 15
ISSN1535-4970
KeywordsAged, Aged, 80 and over, Animals, Biomarkers, Cigarette Smoking, Disease Progression, Female, Follow-Up Studies, Humans, Male, Metformin, Mice, Mice, Inbred C57BL, Middle Aged, Protective Agents, Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema, Treatment Outcome
Abstract

Cigarette smoke (CS) inhalation triggers oxidative stress and inflammation, leading to accelerated lung aging, apoptosis, and emphysema, as well as systemic pathologies. Metformin is beneficial for protecting against aging-related diseases. We sought to investigate whether metformin may ameliorate CS-induced pathologies of emphysematous chronic obstructive pulmonary disease (COPD). Mice were exposed chronically to CS and fed metformin-enriched chow for the second half of exposure. Lung, kidney, and muscle pathologies, lung proteostasis, endoplasmic reticulum (ER) stress, mitochondrial function, and mediators of metformin effects and/or were studied. We evaluated the association of metformin use with indices of emphysema progression over 5 years of follow-up among the COPDGene (Genetic Epidemiology of COPD) study participants. The association of metformin use with the percentage of emphysema and adjusted lung density was estimated by using a linear mixed model. Metformin protected against CS-induced pulmonary inflammation and airspace enlargement; small airway remodeling, glomerular shrinkage, oxidative stress, apoptosis, telomere damage, aging, dysmetabolism and ; and ER stress. The AMPK (AMP-activated protein kinase) pathway was central to metformin's protective action. Within COPDGene, participants receiving metformin compared with those not receiving it had a slower progression of emphysema (-0.92%; 95% confidence interval [CI], -1.7% to -0.14%;  = 0.02) and a slower adjusted lung density decrease (2.2 g/L; 95% CI, 0.43 to 4.0 g/L;  = 0.01). Metformin protected against CS-induced lung, renal, and muscle injury; mitochondrial dysfunction; and unfolded protein responses and ER stress in mice. In humans, metformin use was associated with lesser emphysema progression over time. Our results provide a rationale for clinical trials testing the efficacy of metformin in limiting emphysema progression and its systemic consequences.

DOI10.1164/rccm.202012-4510OC
Alternate JournalAm J Respir Crit Care Med
PubMed ID34033525
PubMed Central IDPMC8521702
Grant ListP50 MD010431 / MD / NIMHD NIH HHS / United States
U01 HL089897 / HL / NHLBI NIH HHS / United States
R01 HL142769 / HL / NHLBI NIH HHS / United States
U01 HL089856 / HL / NHLBI NIH HHS / United States
P50 ES018176 / ES / NIEHS NIH HHS / United States
R01 HL139617 / HL / NHLBI NIH HHS / United States
R01 HL149744 / HL / NHLBI NIH HHS / United States
R01 HL132523 / HL / NHLBI NIH HHS / United States